On July 2, 2026 OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, reported that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company’s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, click here.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Management will provide an overview of OnKure’s strategy for designing its portfolio of next-generation pan-mutant PI3Kα inhibitors.
A live question and answer session will follow the formal presentations.
About Benjamin F. Cravatt, PhD
Benjamin F. Cravatt, PhD, is Professor and Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute. His research group has developed several innovative chemical technologies that enable and expand protein and drug discovery on a global scale. Further application of these methods has offered insights to biological pathways that play important roles in human physiology and disease. Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996. Professor Cravatt joined the faculty at TSRI in 1997. Dr. Cravatt is co-founder of several biotechnology companies, including Activx Biosciences, Abide Therapeutics, Vividion Therapeutics, and Belharra Therapeutics. Dr. Cravatt’s honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, the ASBMB Merck Award, the Wolf Prize in Chemistry, the Heinrich Wieland Prize, the Tetrahedron Award for Creativity in Bioorganic and Medicinal Chemistry, The NAS Award in Chemical Science, and memberships in the National Academies of Inventors, Medicine, and Sciences.
About Robert Abraham, PhD
Robert Abraham, PhD, currently serves as the Chief Scientific Officer at Engine Biosciences. He has previously held leadership roles in several successful biotechnology companies, including Odyssey Therapeutics and Vividion Therapeutics. Prior to entering the biotech sector, Bob was Chief Scientific Officer of the Oncology R&D Group at Pfizer, where he led teams that delivered multiple clinical candidates and 11 FDA-approved oncology drugs. One of those clinical candidates, gedatolisib, is a pan-PI3K/mTOR inhibitor, which has recently delivered highly promising clinical data in ER+ HER2- breast cancer patients. Before joining the pharmaceutical industry, Bob was a prolific immunology and pharmacology researcher with over 230 scientific publications while at Sanford-Burnham-Prebys Medical Research Institute, Duke University Medical Center, and the Mayo Clinic. His research accomplishments included the molecular cloning and functional characterization of the key PI3K pathway component, mTOR. He is also a member of the scientific advisory boards of several public and private companies, and a retained scientific advisor for Google Ventures.
About Next-Generation PI3Kα Pan-Mutant Programs
OnKure is advancing a portfolio that includes two next-generation PI3Kα pan-mutant inhibitor programs, OKI-345 for breast cancer and OKI-355 for vascular anomalies. These candidates are designed to selectively inhibit mutant PI3Kα while sparing wildtype PI3Kα, with the potential to deliver a wider therapeutic index while avoiding class-limiting toxicities associated with first-generation PI3Kα inhibitors. By providing high and sustained target coverage across all hotspot PI3Kα mutations, these programs are designed to support the potential for deep and durable responses as both monotherapy and in combination regimens. In addition, the Company’s pan-mutant candidates are designed to have minimal drug-drug interaction potential, supporting broad combinability with current standards of care. Together with a commanding intellectual property estate, OnKure believes it is well positioned to address a significant unmet need across various PI3Kα-driven indications.
PI3Kα mutations represent the most common driver alterations in key subtypes of vascular anomalies, where PIK3CA variants lead to dysregulated signaling that promotes abnormal cell growth, proliferation, and survival. OnKure believes that OKI-355 has significant potential to address this large and underserved patient population as a differentiated systemic chronic therapy.
OnKure plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for each of OKI‑345 and OKI‑355 in the first half of 2027.
(Press release, OnKure Therapeutics, JUL 2, 2026, View Source [SID1234669056])